It is high time for the scholarly societies to standardize the bronchodilator responsiveness in children
Main Article Content
Keywords
ATS/ERS, bronchodilator reversibility, FEV1, FVC, GINA, spirometry
Abstract
Letter to the editor re: Mallol J, Riquelme C, Aguirre V, Martinez M, Gallardo A, Sanchez C, et al. Value of bronchial reversibility to salbutamol, exhaled nitric oxide and responsiveness to methacholine to corroborate the diagnosis of asthma in children. Allergol Immunopathol (Madr). 2020;48(3):214–22. https://doi.org/10.1016/j.aller.2019.11.001
References
1. Mallol J, Riquelme C, Aguirre V, Martinez M, Gallardo A, Sanchez C, et al. Value of bronchial reversibility to salbutamol, exhaled nitric oxide and responsiveness to methacholine to corroborate the diagnosis of asthma in children. Allergol Immunopathol (Madr). 2020;48(3):214–22. 10.1016/j.aller.2019.11.001
2. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68. 10.1183/09031936.05.00035205
3. Waalkens HJ, Merkus PJ, van Essen-Zandvliet EE, Brand PL, Gerritsen J, Duiverman EJ, et al. Assessment of bronchodilator response in children with asthma. Dutch CNSLD Study Group. Eur Respir J. 1993;6(5):645–51.
4. Masekela R, Gray D, Verwey C, Halkas A, Jeena PM. Paediatric spirometry guideline of the South African Thoracic Society: Part 1. S Afr Med J. 2013;103(12 Suppl 2):1036–41. 10.7196/SAMJ.7239
5. Mahut B, Bokov P, Delclaux C. Abnormalities of plethysmographic lung volumes in asthmatic children. Respir Med. 2010;104(7):966–71. 10.1016/j.rmed.2010.01.015
6. Dufetelle E, Mulier G, Taytard J, Boizeau P, Le Roux E, Beydon N. Peripheral obstruction without airflow limitation is rare and not specific to asthma in children. Pediatr Pulmonol. 2020;n/a:(n/a). 10.1002/ppul.25222
7. Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O’Byrne PM. The global initiative for asthma (GINA): 25 years later. Eur Respir J. 2019;54(2). 10.1183/13993003.00598-2019
8. GRAPP (Research Group on Advances in Pediatric Pneumology). Pulmonary function tests for the assessment and monitoring of asthma in children above 3 years of age. Rev Mal Respir. 2003;20:638–43.
9. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2019. Available from: https://www.sign.ac.uk/media/1773/sign158-updated.pdf (Last visit 3 January 2021).
10. GINA (Global Initiative for Asthma). Global strategy for asthma management and prevention. 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf (Last visit 3 January 2021).
11. NAEPP (National Asthma Education and Prevention Program). Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94. 10.1016/j.jaci.2007.09.029
12. Ben Saad H. Promoting the inclusion of lung volumes in the reversibility evaluation. Respir Care. 2017;62(2):255–6. 10.4187/respcare.05277
13. Saad HB, Préfaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther. 2008;21(5):767–73. 10.1016/j.pupt.2008.04.005
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38. 10.2147/COPD.S127336
15. Torén K, Bake B, Olin AC, Engström G, Blomberg A, Vikgren J, et al. Measures of bronchodilator response of FEV1, FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study. Int J Chron Obstruct Pulmon Dis. 2017;12:973–80. 10.2147/COPD.S127336
16. Guezguez F, Ben Saad H. What constitutes a “clinically significant” bronchodilator response in children? Eur Respir J. 2020;55(5). 10.1183/13993003.00207-2020
2. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68. 10.1183/09031936.05.00035205
3. Waalkens HJ, Merkus PJ, van Essen-Zandvliet EE, Brand PL, Gerritsen J, Duiverman EJ, et al. Assessment of bronchodilator response in children with asthma. Dutch CNSLD Study Group. Eur Respir J. 1993;6(5):645–51.
4. Masekela R, Gray D, Verwey C, Halkas A, Jeena PM. Paediatric spirometry guideline of the South African Thoracic Society: Part 1. S Afr Med J. 2013;103(12 Suppl 2):1036–41. 10.7196/SAMJ.7239
5. Mahut B, Bokov P, Delclaux C. Abnormalities of plethysmographic lung volumes in asthmatic children. Respir Med. 2010;104(7):966–71. 10.1016/j.rmed.2010.01.015
6. Dufetelle E, Mulier G, Taytard J, Boizeau P, Le Roux E, Beydon N. Peripheral obstruction without airflow limitation is rare and not specific to asthma in children. Pediatr Pulmonol. 2020;n/a:(n/a). 10.1002/ppul.25222
7. Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O’Byrne PM. The global initiative for asthma (GINA): 25 years later. Eur Respir J. 2019;54(2). 10.1183/13993003.00598-2019
8. GRAPP (Research Group on Advances in Pediatric Pneumology). Pulmonary function tests for the assessment and monitoring of asthma in children above 3 years of age. Rev Mal Respir. 2003;20:638–43.
9. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2019. Available from: https://www.sign.ac.uk/media/1773/sign158-updated.pdf (Last visit 3 January 2021).
10. GINA (Global Initiative for Asthma). Global strategy for asthma management and prevention. 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf (Last visit 3 January 2021).
11. NAEPP (National Asthma Education and Prevention Program). Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94. 10.1016/j.jaci.2007.09.029
12. Ben Saad H. Promoting the inclusion of lung volumes in the reversibility evaluation. Respir Care. 2017;62(2):255–6. 10.4187/respcare.05277
13. Saad HB, Préfaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther. 2008;21(5):767–73. 10.1016/j.pupt.2008.04.005
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38. 10.2147/COPD.S127336
15. Torén K, Bake B, Olin AC, Engström G, Blomberg A, Vikgren J, et al. Measures of bronchodilator response of FEV1, FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study. Int J Chron Obstruct Pulmon Dis. 2017;12:973–80. 10.2147/COPD.S127336
16. Guezguez F, Ben Saad H. What constitutes a “clinically significant” bronchodilator response in children? Eur Respir J. 2020;55(5). 10.1183/13993003.00207-2020
Article Sidebar
Published
Mar 1, 2021
Article Details
How to Cite
Ben Saad, H. (2021). It is high time for the scholarly societies to standardize the bronchodilator responsiveness in children. Allergologia Et Immunopathologia, 49(2), 225-227. https://doi.org/10.15586/aei.v49i2.98
Section
Letter to Editor
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Ben Saad, H. (2021). It is high time for the scholarly societies to standardize the bronchodilator responsiveness in children. Allergologia Et Immunopathologia, 49(2), 225-227. https://doi.org/10.15586/aei.v49i2.98